GLP-1 and Dual/Triple Agonists Show Promise for Treating Fatty Liver Disease, with Newer Agents Improving Fibrosis | Research

The takeaway

While single GLP-1 agonists (liraglutide, semaglutide) improve fatty liver inflammation but not fibrosis, dual agonists tirzepatide (GIP/GLP-1) and survodutide (glucagon/GLP-1) show higher rates of both MASH resolution and fibrosis improvement.

32.4% global prevalence
MASLD affects one-third of the world's population, with limited treatment options until GLP-1 and dual agonists emerged

What the researchers found

Dual receptor agonists tirzepatide (GIP/GLP-1) and survodutide (GCG/GLP-1) demonstrate higher rates of MASH resolution and fibrosis improvement compared to single GLP-1 agonists alone.

Why it matters

MASLD affects 32.4% of the global population and has very few approved treatments. Fibrosis progression is the strongest predictor of liver-related death. Finding drugs that improve fibrosis — not just inflammation — is critical for reducing the burden of liver disease.

The numbers in context

Global prevalence of MASLD is estimated at 32.4%. The disease is linked to increased cardiovascular, metabolic, and cancer risk.

How the study worked

Narrative review of clinical trial data for GLP-1 RAs, GIP/GLP-1 dual agonists, and GCG/GLP-1 dual agonists in the treatment of MASLD/MASH.

Who was studied

Adults with metabolic dysfunction-associated steatotic liver disease

What this study cannot tell us

Review article without systematic methodology. Clinical trials of dual agonists for MASH are still in relatively early stages. Gastrointestinal tolerability remains a significant concern. Long-term hepatic outcomes are not yet established for any of these agents.

How to read the evidence

Moderate evidence from clinical trials of GLP-1 drugs for liver disease. Evidence for dual agonists is still preliminary but encouraging.

When this study was published

Published in 2024. Captures the rapidly evolving therapeutic landscape for MASLD/MASH.

The bigger picture

The evolution from single to multi-receptor agonists mirrors the broader trend in obesity medicine. For liver disease, the addition of glucagon receptor activation (which directly promotes fat breakdown in the liver) may explain the superior fibrosis improvement seen with newer dual agonists.

Questions still open

Will triple agonists like retatrutide show even greater liver benefits than dual agonists?
Can combination therapy with a GLP-1 RA and a dedicated anti-fibrotic agent achieve better outcomes?
What is the optimal duration of treatment needed to reverse fibrosis with these agents?

Common questions

Can GLP-1 drugs treat fatty liver disease?

GLP-1 drugs like semaglutide can reduce liver inflammation and fat content, and some patients achieve complete MASH resolution. However, they haven't consistently improved liver fibrosis (scarring), which is the key driver of serious liver outcomes.

Why might dual agonists work better for liver disease?

Drugs that also activate glucagon receptors (like survodutide) directly promote fat breakdown in liver cells, which GLP-1 alone doesn't do as effectively. This additional mechanism may explain why dual agonists show better results for both inflammation and fibrosis.

Read the original research

GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.

World journal of gastroenterology, 30(48), 5205-5211

View on PubMed ↗Publisher’s paper ↗

Citation

Singh, Anmol; Sohal, Aalam; Batta, Akash. (2024). GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.. World journal of gastroenterology, 30(48), 5205-5211. https://doi.org/10.3748/wjg.v30.i48.5205